Literature DB >> 15647715

Advances in diabetes for the millennium: nutritional therapy of type 2 diabetes.

Marc Rendel1.   

Abstract

Dietary modification is useful in both type 1 and type 2 diabetes. Glucose levels after a meal are largely determined by carbohydrate intake. Decreased intake of simple carbohydrates and increased fiber consumption lower postprandial glucose. Obesity has become epidemic in the United States and has dramatically increased the incidence of type 2 diabetes by augmenting insulin resistance. Dietary treatment of obesity has been frustrating. Success will require education in using foods with high fiber contents, low glycemic indexes, and low saturated fat levels. The use of natural foods must be supplemented by the use of semisynthetic foods with desirable properties. The educational efforts required are substantial and must be recognized by third-party reimbursement agencies. Operative procedures to decrease intake or reduce the absorption of food are being used with increasing frequency. Bariatric surgery is often successful in inducing a substantial loss of weight; however, this success must be balanced against the complications of surgery, which can be considerable. The pharmacologic approaches to treatment of obesity have focused primarily on anorexigenic agents. Several polypeptides that induce satiety are currently under study, including leptin and glucagon-like peptide-1 (GLP-1). Orlistat has been used to induce the malabsorption of fat to reduce caloric ingestion. Of the currently used oral hypoglycemics, metformin and the disaccharidase inhibitors have the best tendency to promote weight loss. There is active research on the uncoupling proteins that induce thermogenesis and promote the dissipation of calories. The beta-3 agonists act through the uncoupling proteins. The thiazolidinediones tend to promote weight gain through the PPAR gene locus. Agents that antagonize this effect could induce weight loss. The future will undoubtedly bring us drugs that are effective in causing weight loss. The advent of drugs to successfully combat obesity will substantially improve public health.

Entities:  

Mesh:

Year:  2004        PMID: 15647715      PMCID: PMC1474821     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  38 in total

1.  President's page: The epidemic of type 2 diabetes and obesity in the U.S.: cause for alarm.

Authors:  G A Beller
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

2.  Dietary treatment of diabetes mellitus.

Authors:  M Rendell
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

3.  The continuing epidemic of obesity in the United States.

Authors:  A H Mokdad; M K Serdula; W H Dietz; B A Bowman; J S Marks; J P Koplan
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

4.  Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin?

Authors:  E Doucet; S St Pierre; N Alméras; P Mauriège; D Richard; A Tremblay
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 5.  Orlistat, a new lipase inhibitor for the management of obesity.

Authors:  A M Heck; J A Yanovski; K A Calis
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

Review 6.  Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.

Authors:  C A Luque; J A Rey
Journal:  Ann Pharmacother       Date:  1999-09       Impact factor: 3.154

7.  Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist.

Authors:  J Margareto; E Larrarte; A Marti; J A Martinez
Journal:  Biochem Pharmacol       Date:  2001-06-15       Impact factor: 5.858

8.  A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans.

Authors:  H Esterbauer; C Schneitler; H Oberkofler; C Ebenbichler; B Paulweber; F Sandhofer; G Ladurner; E Hell; A D Strosberg; J R Patsch; F Krempler; W Patsch
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

9.  Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients--what have we learned?

Authors:  K D Higa; K B Boone; T Ho
Journal:  Obes Surg       Date:  2000-12       Impact factor: 4.129

Review 10.  Thermogenic drugs as a strategy for treatment of obesity.

Authors:  A Astrup
Journal:  Endocrine       Date:  2000-10       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.